Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the presentation of new preclinical data on PH-894, an innovative therapeutic based on their proprietary self-delivering RNAi platform, at the ASGCT 25th Annual Meeting from May 16-19, 2022. This research focuses on improving the phenotype of HER2-CAR-T cells during expansion. The poster session is scheduled for May 16, 2022, from 5:30 PM - 6:30 PM EDT at the Walter E. Washington Convention Center in Washington, D.C., highlighting the company's advancements in immuno-oncology therapeutics.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) appointed Patricia A. Bradford as an independent director to its Board. Bradford, with over 40 years of HR and financial experience, previously held senior roles at Unisys Corporation and Deloitte. Chairman Robert Bitterman expressed confidence in her ability to contribute significantly during a pivotal period as the first INTASYL therapeutic compounds enter clinical trials. Bradford also emphasizes her excitement to work on advancing the company’s portfolio of immuno-oncology therapies aimed at cancer treatment.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has commenced patient enrollment in the Phase 1b clinical trial for PH-762, aimed at treating advanced melanoma. This trial represents a significant milestone, being the first clinical study of PH-762, which targets PD-1 to enhance immune response against cancer cells. Conducted at the Gustave Roussy Institute, it will assess the safety, tolerability, and anti-tumor activity of PH-762. The study is crucial as there are currently no approved neoadjuvant treatments for advanced melanoma, and preclinical data suggest promising efficacy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that its in vivo data on PH-762, a self-delivering RNAi therapeutic, indicating tumor clearance, will be presented at the Society for Immunotherapy of Cancer (SITC) Workshop on April 21-22, 2022, in San Diego. The presentation is titled 'Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors.' The session is scheduled for April 21 from 5:20 p.m. to 6:20 p.m. PT.
This highlights Phio's commitment to developing innovative immuno-oncology treatments.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced positive preclinical data for PH-894, a self-delivering RNAi compound targeting BRD4. The data, to be presented at the AACR Annual Meeting 2022, show that PH-894 inhibited tumor growth in PD-1 responsive and insensitive models and enhanced the efficacy of anti-PD-1 antibody therapy on both treated and untreated distal tumors. The results highlight PH-894's potential as a standalone therapy and in combination with anti-PD-1 treatment, addressing a significant medical need for patients unresponsive to current therapies.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its transition into a clinical-stage company with the initiation of its first clinical study for PH-762 targeting advanced melanoma. The company reported a net loss of $13.3 million for the year ended December 31, 2021, up from $8.8 million in 2020. The company holds $24.1 million in cash, sufficient to fund operations into the second quarter of 2023. Upcoming milestones include starting patient enrollment for PH-762 and new data presentations related to its pipeline in 2022.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the upcoming presentation of new preclinical data on its RNAi compound PH-894, targeting BRD4, at the AACR Annual Meeting 2022 in New Orleans from April 8-13, 2022. The poster session will discuss PH-894's potential to provide abscopal efficacy toward untreated distal tumors and enhance systemic anti-PD-1 antibody therapy effectiveness. The presentation, led by Benjamin Cuiffo and accessible in person and virtually, is scheduled for April 13, 2022, from 9:00 AM to 12:30 PM.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced the initiation of efficacy animal studies focusing on its INTASYL-based antiviral compounds against SARS-CoV-2. This follows earlier positive laboratory results. The compounds target two virus-related and one host-related target, with three compounds selected for further testing in a validated mouse model. The INTASYL platform's efficiency highlights its potential for rapid development of antiviral therapies to combat COVID-19 variants. The company's ongoing commitment includes immuno-oncology programs while addressing the pandemic's challenges.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) received regulatory clearance from the French National Agency for the Safety of Medicines and Health Products to initiate a clinical trial for its lead product candidate, PH-762, targeting melanoma. This Phase 1b trial will assess the safety, tolerability, and anti-tumor activity of PH-762, which works by reducing PD-1 expression to enhance cancer cell recognition and destruction by immune cells. The company aims to start dosing patients in Q1 2022, marking a significant milestone in the development of its INTASYL immuno-oncology platform.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, scheduled from January 10–13, 2022. Dr. Gerrit Dispersyn, the CEO, will present on the firm's innovative immuno-oncology therapeutics using its proprietary INTASYL™ RNAi platform, aimed at enhancing immune response against tumors. The presentation will be available on-demand starting at 7 a.m. EST on January 10. Interested parties can access the webcast through the company's website, where it will remain archived for 90 days.